SKI306X compound is a herbal mixture. This plant was in
oriental medicine and was clinically approved for the treatment of
osteoarthritis (OA) in Korea.
SKI306X was previously found to have anti-inflammatory,
analgesic and cartilage protective effects in several experimental models. In this study,
SKI306X was investigated for its gastro-sparing effects on the gastric mucosa comparing with those of
diclofenac, a conventional
NSAID, and
celecoxib, a
cyclooxygenase-2 (COX-2) specific inhibitor. To investigate acute gastric damaging properties of
SKI306X, the stomach of the animals was histologically and immuno-histochemically examined after single or repeated administration, and
SKI306X demonstrated excellent gastric tolerability.
SKI306X did not cause significant gastric irritation, erosion, or ulceration up to the orally administered dose of 2 g/kg and the intraperitoneal (i.p.) dose of 125 mg/kg. In contrast,
diclofenac caused mucosal erosion, ulceration and
bleeding at clinically effective doses. To determine the mode of gastro-sparing action,
eicosanoid synthesis was examined in gastric mucosa and blood.
SKI306X significantly decreased gastric and blood
leukotriene B(4) (LTB(4)) production. However,
SKI306X showed either no effect or a slight increase in levels of
prostaglandin E(2) (
PGE(2)). In addition, gastro-protective effects of
SKI306X were exhibited by suppressing
diclofenac-induced erosion and ulceration of gastric mucosa in a rat model and the possible mechanism of these effects were investigated. These studies demonstrated that
SKI306X did not produce any significant damage up to dose of 2 g/kg and was effective in significantly protecting the damage associated to
diclofenac-induced gastric ulcerations.
SKI306X could spare the gastric mucosa through significantly suppressing gastric
leukotriene (LT) synthesis.